HLA-C and neoplasm: Compared to engineered TCRs, CARs are independent of MHC expression and co-stimulation; therefore, they are not influenced by loss of MHC-associated antigen presentation by tumor cells, which commonly represents a major mechanism of immune evasion from TCR-T cell therapy [21,50].